NCT05341570View on ClinicalTrials.gov

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668

PHASE1UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

BPI-21668

Subjects will receive BPI-21668 until disease progression

Trial Locations (1)

100021

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

NCT05341570 - A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 | Biotech Hunter | Biotech Hunter